Date: 2015-06-11
Type of information: Nomination
Compound:
Company: Reneuron (UK)
Therapeutic area: Rare diseases - Genetic diseases - Regenerative medicine - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 11, 2015, ReNeuron, a leading UK-based stem cell therapy company, announced two further senior management appointments. The appointments are part of a phased restructuring and broadening of the Company\'s executive and non-executive management as ReNeuron moves into its next phase of development. Dr Julian Howell will be joining ReNeuron as Chief Medical Officer, with responsibility for clinical development activities at the Company. Dr Howell has held a number of leadership roles in clinical development during the last 15 years, bringing small molecules and biological products through all phases of clinical development in Europe and the US. He joins ReNeuron from Shield Therapeutics, where he held the role of Group Medical Director. Prior to that, Dr Howell led the clinical team at ProStrakan, contributing to multiple US and EU new product approvals in oncology supportive care, GI and pain treatments. He gained medical and surgical qualifications in the UK and worked in the UK health service before completing an MBA at Cranfield University and joining the pharmaceutical industry, initially at SmithKlineBeecham and subsequently in senior clinical and medical affairs roles at Roche, Chiron and Pharmion. Shaun Stapleton has been appointed as Head of Regulatory Affairs at ReNeuron. Mr Stapleton joins ReNeuron from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, Mr Stapleton began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry. He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.
Financial terms:
Latest news:
